Evidence map›Paper›PMID 35080883›Full record

ArticleJournal of medicinal chemistry2022

Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors.

Mirko Scortichini, Riham Mohammed Idris, Susanne Moschütz, Antje Keim, Veronica Salmaso, Clemens Dobelmann, Paola Oliva, Karolina Losenkova, Heikki Irjala, Samuli Vaittinen and 6 more

Open access · greenAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Mirko ScortichiniMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Riham Mohammed IdrisPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Susanne MoschützCenter for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany.
Antje KeimCenter for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany.
Veronica SalmasoMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Clemens DobelmannEuropean Institute for Molecular Imaging (EIMI), University of Münster, Waldeyerstrasse 15, D-48149 Münster, Germany.
Paola OlivaMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Karolina LosenkovaMedicity Research Laboratory, University of Turku, 20520 Turku, Finland.
Heikki IrjalaDepartment of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital and Turku University, 20520 Turku, Finland.
Samuli VaittinenDepartment of Pathology, Turku University Hospital and Turku University, 20520 Turku, Finland.
Jouko SandholmTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Gennady G YegutkinMedicity Research Laboratory, University of Turku, 20520 Turku, Finland.ORCID 0000-0001-6684-7982
Norbert SträterCenter for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany.ORCID 0000-0002-2001-0500
Anna JunkerEuropean Institute for Molecular Imaging (EIMI), University of Münster, Waldeyerstrasse 15, D-48149 Münster, Germany.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.ORCID 0000-0002-0013-6624
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.ORCID 0000-0001-8104-1493
National Institutes of Health · USLeipzig University · DETurku University Hospital · FIUniversity of Bonn · DEUniversity of Münster · DEUniversity of Turku · FIÅbo Akademi University · FI

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Development Of P2Y Receptor LigandsZIADK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$8.9M
Functionalized Congeners Of Bioactive CompoundsZIADK031115 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$5.3M
Intramural NIH HHS ZIA DK031116Intramural NIH HHS ZIA DK031117
6 · The paper itself

Abstract

We recently reported

Indexed as

5'-NucleotidaseAdultCytosine NucleotidesDiphosphonatesEnzyme InhibitorsGPI-Linked ProteinsHumansMaleMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureNeoplasmsPalatine TonsilProtein BindingStructure-Activity Relationship5'-NucleotidaseCytosine NucleotidesDiphosphonatesEnzyme InhibitorsGPI-Linked ProteinsNT5E protein, human

Identifiers

PMID35080883
PMCPMC8865918
OpenAlexW4210556679

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.